Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Nuvelo up after restarting SONOMA-3

NUVO gained $0.27 (17%) to $1.90 on Wednesday after it restarted the SONOMA-3 trial of

Read the full 157 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE